Glaucoma is a leading cause of blindness in virtually every country. Development of an accurate diagnostic test for presymptomatic detection of individuals at risk is an urgent requisition for this condition. Herein, we report mapping of a new adult-onset primary open-angle glaucoma (POAG) locus on 5q22.1 (GLC1G ) and identification of its defective gene. Mutation screening of seven candidate genes from the GLC1G critical region (2 Mb between D5S1466 and D5S2051) identified only one significant alteration in the WDR36 (WD40-repeat 36) gene. This mutation (i.e. D658G) was segregated in all affected members of our first GLC1G-linked family but it was absent in 476 normal control chromosomes. Further screening of WDR36 in a total of 130 POAG families revealed 24 DNA variations. Overall, four mutations (N355S, A449T, R529Q and D658G) were identified in 17 (5.02 -6.92%) unrelated POAG subjects, 11 with high-pressure and six with low-pressure glaucoma. These mutations were absent in a minimum of 200 normal control chromosomes and, further they were conserved between WDR36 orthologues in mouse, rat, dog, chimp and human. WDR36 is a novel gene with 23 exons, which encodes for 951 amino acids and a protein with multiple G-beta WD40 repeats. By northern blotting, two distinct mRNA transcripts of 5.9 and 2.5 kb were observed in human heart, placenta, liver, skeletal muscle, kidney and pancreas. WDR36 gene expression in lens, iris, sclera, ciliary muscles, ciliary body, trabecular meshwork, retina and optic nerve were established by RT -PCR. In mouse, two transcripts of 3.5 and 2.9 kb showed analogous expression patterns to human. mRNA expressions were detected in 7-, 11-, 15-and 17-day-old developing mouse embryos. In summary, WDR36 is a novel causative gene for adult-onset POAG at the GLC1G locus. Specific ocular expressions and observed mutations are consistent with WDR36 role in etiology of both high-and low-pressure glaucoma.
INTRODUCTION
Glaucoma is a group of ocular disorders characterized by a specific pattern of optic nerve and visual field defects. This condition is one of the two leading causes of blindness, affecting over 67 million people worldwide (1) . Open-angle glaucoma is usually asymptomatic until the late stages of the disease, by which time significant and irreversible optic nerve damage has already taken place (2, 3) . As the sensitivity of current diagnostic techniques is suboptimal, the diagnosis of glaucoma is usually made once an irreversible damage has already occurred. As glaucoma related visual loss is preventable in many cases, there is an urgent need to diagnose glaucoma at its early stages and to institute appropriate neuroprotective management of the ganglion cells (4, 5) . Mapping, cloning and identification of novel mutations involved in the etiology of glaucoma provide a significant opportunity for presymptomatic diagnosis, improved prognosis and better understanding of the etiology of this blinding condition.
Human Molecular Genetics, Vol. 14, No. 6 # Oxford University Press 2005; all rights reserved *To whom correspondence should be addressed. Tel: þ1 8606793629; Fax: þ1 8606797524; Email: mansoor@neuron.uchc.edu Human Molecular Genetics, 2005, Vol. 14, No. 6 725-733 doi:10.1093/hmg/ddi068 Advance Access published on January 27, 2005 Adult-onset primary open-angle glaucoma (POAG; MIM no. 137760) is the commonest form of this ocular group, usually manifesting itself after the age of 40 years (6, 7) . The prevalence of POAG is 1-2% over age 50 in white populations (8) and four to five times greater in black populations of the same age (9) . Clinical diagnosis of all groups is based on characteristic changes of the optic nerve head and visual field, which are usually accompanied by increased intraocular pressure (IOP) (10) . Family history is an important risk factor for POAG, and genetic study of families shows that dominant genes are predominantly involved in this condition (7, 11, 12) .
During the last decade, a total of six genetic loci (13 -18) and two genes have been reported for POAG: myocilin (MYOC ) is primarily mutated in juvenile-onset subjects (19) , whereas optineurin (OPTN ) is mainly mutated in low pressure POAG individuals (20, 21) . Here, we report chromosomal mapping of a new POAG locus on 5q22.1 (designated as GLC1G ) and identification of its causative gene, WDR36 (WD40-repeat 36), from within this region. We further present the first expression analysis of this gene in a variety of human ocular and non-ocular tissues. For an evolutionary comparative analysis, we further determined expression of the homologue of this gene (Wdr36 ) in various stages of mouse embryonic developments as well as a group of tissues from the adult animals.
RESULTS

Positional mapping of a new locus (GLC1G ) for adult-onset POAG
Initially, genome scans of two large POAG families (i.e. POAG-002 and POAG-527) with 20 affected and nine glaucoma suspects were used to obtain a provisional hint of linkage to the 5q33 -q35 region (22) . Extended saturation mapping established critical recombination in two of the affected individuals in POAG-002 and, therefore, excluded genetic linkage of this family to this region of 5q. However, additional genotyping in POAG-527 revealed consistent sharing of an extended affected haplotype from 5q21.3 (D5S1466) to 5q35.2 (D5S498) in all seven affected members of this family (23) . Therefore, in light of this new linkage information and due to a discrepancy that currently exists between genetic linkage and physical map position of several DNA markers from this region of chromosome 5 (including D5S1466), the upper physical boundary for this new POAG locus is now 5q21.3 and not 5q33 as initially envisaged (22) .
After a hint of linkage was observed with the 5q region, seven additional POAG families with a total of 194 individuals and 31 living affected subjects were genotyped. Only two of these families were consistent with linkage to the same 5q region. Further saturation mapping in these families confined this new linkage to an interval of 35 Mb (Fig. 1 ) that is flanked by D5S1466 (5q21.3) and D5S1480 (5q31.3). Additional recombination in a subject with ocular hypertension (OH) and for DNA marker of D5S404 (5q23.1) suggested that the identified genetic linkage may be limited to 7 Mb (Fig. 1) . In a parallel study, a group of 638 individuals (including more than 400 affected subjects) in 139 POAG families were being screened in our laboratory for the entire genome. As this screening also covered this newly identified region on 5q, a number of new families showed potential linkage to this region. Altogether, a total of seven families were consistent with linkage to this region of 5q. Table 1 shows individual and multi-point LOD score values for three closely linked DNA markers of D5S1462, D5S2501 and D5S1505 (Fig. 1) . This newly identified POAG locus has now been designated as GLC1G by HUGO Gene Nomenclature Committee (HGNC). Recently, Samples et al. (24) and Kramer et al. (25) reported linkage in a single adult-onset POAG family and, within a 6.6 Mb region ( Fig. 1) that is flanked by D5S1721 (5q21.2) and D5S2051 (5q22.1). Taken together, these two overlapping linkage data defined the critical region of the GLC1G locus between D5S1466 (5q21.3) and D5S2051 (5q22.1) and within a region of 2 Mb (Fig. 1) . This newly identified GLC1G locus provided an opportunity for rapid mutation screening and identification of the defective gene at this locus.
GLC1G candidate genes screening
The critical region of the GLC1G locus contains seven known genes (MAN2A1, AK125070, BC017169, TSLP, WDR36, CAMK4 and STARD4 ) and at least three other predicted genes (LOC153778, LOC441101 and LOC441102). For each of the seven known genes (Fig. 1) , a series of genomic primers were made and their respective coding exons were PCR amplified and screened for mutation by direct DNA sequencing. Analysis of genomic DNA from at least two affected subjects of the original GLC1G-linked family of POAG-527 revealed four sequence alterations in only two genes. Three of these variations (i.e. IVS625A.G, S337S and A413V in CAMK4 ) were polymorphisms and only one sequence change in WDR36 proven to be significant. The observed variation in this gene was a single heterozygous DNA alteration in exon 17 (c.1973A.G; GAC.GGC) that is predicted to change aspartic acid (acidic) to glycine (neutral and polar) at amino acid 658 (D658G). This mutation (Fig. 2D ) was observed in seven affected (with mean age of 63.7 years) and nine asymptomatic gene carriers (with mean age of 40.4 years) but it was absent in nine normal members of this family (with mean age of 45.3 years) and another six married-in normal spouses (Fig. 2E ). Screening of a total of 476 normal control chromosomes by restriction enzyme digestion (Bgl I) showed that this mutation is absent in all the normal subjects tested. Direct sequencing of WDR36 in another 129 unrelated affected glaucoma probands (including the six GLC1G-linked families) identified additional 23 DNA alterations ( Table 2 ). Three of these alterations (N355S, A449T and R529Q) ( Fig. 2A -C) were considered disease causing, as they were not present in any of the public databases and in a group of at least 200 tested chromosomes from normal control subjects. We directly sequenced the genomic DNA of at least one affected subject from each of the original seven linked families. However, two of these families did not show any DNA variations in the coding regions of the WDR36 gene. Therefore, it is possible that other mutations interfering with the mRNA splicing machinery, mutations within the promoter of this gene or presence of other DNA rearrangements such as insertion, deletion or duplication is responsible for the POAG phenotype in these two families. Alternatively, it is possible that another POAG locus is located within our identified genetic linkage and, therefore, mutations in another gene are responsible for these two families.
Expression study of WDR36 at RNA level As a first step in determining the role of WDR36 in glaucoma pathogenesis, we studied expression of this gene in different human ocular and non-ocular tissues by northern blot and reverse transcriptase -polymerase chain reaction (RT-PCR). Northern blotting of several human non-ocular mRNA samples revealed two different transcripts (i.e. 5.9 and 2.5 kb) that are highly expressed in heart, placenta, liver, skeletal muscle and pancreas (Fig. 3A) . Using RT -PCR, similar WDR36 expressions were also detected in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas (Fig. 3B ). WDR36 expression was also detected in a number of ocular tissues including lens, iris, sclera, ciliary muscles, ciliary body, trabecular meshwork, retina and optic nerve (Fig. 3C ). As a comparative study, we also determined mRNA expression patterns for the orthologue of this gene (Wdr36 ) in mouse. Northern blotting of Wdr36 in a panel of adult mouse tissues revealed analogous expression patterns to human with only one exception; in skeletal muscle, the expression was stronger in human (Fig. 4A) . Using RT -PCR, high levels of Wdr36 expression were detected in mouse heart, brain, liver, skeletal muscle, kidney, testis and lower expressions in spleen and lung (Fig. 4B) . Study of Wdr36 during various stages of mouse embryonic developments showed that this gene is detectable in 7-day-old embryos ( Fig. 4C) .
DISCUSSION
This article describes mapping of a new locus for POAG (GLC1G ) on the 5q22.1 region and identification of its disease-causing gene, WDR36 (GenBank accession no. NM_139281). As WDR36 is a novel gene, using northern blot analysis we determined the transcript size of this gene in two commercially available human and mouse mRNA blots, and using RT -PCR, we established expression of this gene in human ocular and non-ocular as well as in embryonic and adult mouse tissues.
WDR36 has recently been identified as one of the genes that is uniquely involved in T-cell activation and highly coregulated with interleukin 2 (IL2). This gene encodes for a T-cell activation protein with a minimum of eight WD40 repeats (26) and, therefore, it is also recognized as T-cell activation WD repeat protein (TA-WDRP). This gene contains 23 (Table 2 ). Comparative sequence alignments of this gene among human, chimp, dog, rat and mouse revealed that 11 of these amino acids (except V727) have been fully conserved among these species (Fig. 5) . Evolutionary conservation of the four identified disease-causing mutations (N355S, A449T, R529Q and D658G) in at least five different species and their absence in a minimum of 200 human normal control chromosomes imply that these four amino acids perform a fundamentally important role in the organization of WDR36 protein.
Although one of the WDR36 disease-causing mutations identified in this study (A449T) is not part of a known protein motif, the other three are located in separate G-beta WD40 repeats (Fig. 5) . The N355S mutation in exon 8 maps to the fourth WD40 repeat (covering amino acids 321 -361), the R529Q in exon 13 maps to the sixth WD40 repeat (amino acids 525-567) and D658G in exon 17 maps to the eighth WD40 repeat (amino acids 653 -692). The G proteins are a family of membrane-associated proteins that act as intermediaries in transduction of the signals generated by transmembrane receptors. The G-beta subunit is required for membrane anchoring and receptor recognition. Structurally, the G-beta consists of eight tandem repeats of about 40 residues, each containing a central Trp-Asp dipeptide (thus named WD40 repeats). Therefore, mutations affecting the structure of these WD40 repeats may interfere with interaction of WDR36 with other proteins. This repetitive WD40 segment is also present in over 250 proteins that are encoded by a variety of genes mapping to every one of the human chromosomes. None of the WDR36 detected amino acid alterations in this study was located in the AMP-binding domain (amino acids 553-564) and only one single nucleotide polymorphism or SNP (V727V) was identified from within the Utp21 domain (amino acids 724 -948).
The D658G mutation (Figs 2D and Fig. 5 ) that is located within the eighth WD40 repeat also maps to the C-terminal part of the cytochrome heme cd1 (cyt cd1) domain (amino acids 109 -318 and 537 -686). This 'cyt cd1' is part of a bi-functional enzyme with cytochrome oxidase activity (27) . It is interesting that we have previously identified another member of the cytochrome P450 family (CYP1B1 ) that is involved in the etiology of primary congenital glaucoma (28, 29) . Therefore, there might be a functional association between WDR36 and CYP1B1, as mutations in these two genes are responsible for two different forms of glaucoma.
As D658G mutation was originally observed in five out of 130 unrelated and familial POAG subjects, we further tested for the presence of this one particular mutation in an additional 540 unrelated affected individuals from different POAG subgroups. This mutation creates a new recognition site (Bgl I) thus providing a rapid method for its screening (Fig. 2E) . In total, 13 out of 670 (1.94%) subjects tested were found to be heterozygous for D658G (seven with high-and six with low-pressure glaucoma). Originally, we sequenced the entire of WDR36 gene in a total of 130 familial POAG cases and identified three mutations of N355S, A449T and R529Q in four families (3.08%) and the common mutation of D658G in five families. Altogether, nine out of 130 (6.92%) families that were fully sequenced showed mutations in the WDR36 gene. When additional 540 unrelated affected subjects (268 familial and 272 sporadic) were only tested for presence of -test using Yates correction. c Five D658G mutations identified in the same group of 130 POAG families (3.85%) plus another eight mutations in additional 540 unrelated subjects (i.e. five out of 268 familial and three out of 272 sporadic cases) that were tested only for this one particular mutation. Altogether, 13 D658G mutations were observed in 670 (1.94%) unrelated familial (10/398 or 2.51%) and sporadic (3/272 or 1.10%) cases of POAG. D658G, this mutation was observed in another five familial and three sporadic cases. Altogether, D658G was observed in 2.51% of familial (10 out of 398) and 1.10% of sporadic (three out of 272) cases, thus providing a combined frequency of 1.94% (13 out of 670) for this one mutation alone. When this is added to the frequency of 3.08% obtained from the other three mutations, a minimum mutation rate of 5.02% is obtained for this gene. After the entire of WDR36 gene in the earlier-mentioned 540 familial and sporadic cases is fully sequenced, it is anticipated that additional mutations will be identified thus, altering the mutation frequency of 5.02 -6.92% as presented here. In summary, we identified four different WDR36 mutations in 17 subjects with either high-pressure (65% of subjects) or low-pressure (35% of subjects) POAG. This observation indicates that the WDR36 gene is involved in etiology of both types of glaucoma and IOP, as traditionally used to group these into two separate clinical entities, may not be supported by this study and by recent molecular delineation of this group of optic neuropathies (20, 21) .
We also identified three other amino acid alterations of L25P, A163V and Y216P in a group of 15 POAG subjects ( Table 2) . As these three alterations were absent in all of the public databases, we screened for their presence in 428, 422 and 200 normal control chromosomes, respectively. As the ratio of their presence in the POAG group was significantly higher than that obtained for the normal group (11.55 versus 2.21%, respectively), we considered these as potential disease-susceptibility alterations (Tables 2 and Fig. 5 ). The role of these amino acid variations in the etiology of POAG requires further investigation.
We also observed three amino acid polymorphisms in our POAG or normal control subjects (I264V, M671V and V727V). In addition to these, the Ensembl database lists two other polymorphisms (S90I and A149A) that were not observed in our study. The two other silent amino acid polymorphisms (G134G and V714V) identified in this study were also present in the public EST databases. It is interesting that during this study (Table 2) , we also observed 100% linkage disequilibrium between G134G and Y216P, and 95% between V714V and IVS18þ216C.T. Of the 12 intronic alterations that were identified in this study, only four have previously been deposited in the SNP databases (Table 2) . Therefore, we screened a total of 90 normal control chromosomes for the presence of these previously unreported intronic alterations. As shown in Table 2 , only two of these changes (i.e. IVS7239T.G and IVS8þ 92G.A) were absent in the normal control chromosomes but the significance of their presence in the POAG subjects is not clear at this point and requires further investigation.
As there is limited in silico expression data for WDR36, we studied the mRNA transcripts of this gene in various mouse and human tissues. Using northern analysis two different transcript sizes were detected in human and mouse (Figs 3  and 4) . However, it is not clear at this point whether these two transcripts were produced by alternative splicing or by use of two different promoters. In humans, intense hybridization was observed in heart, placenta, liver, skeletal muscle, kidney and pancreas ( Fig. 3A and B) . In mouse, heart, liver and kidney produced the highest signal ( Fig. 4A and B) . Using RT -PCR, we determined expression of WDR36 in lens, iris, sclera, ciliary muscles, ciliary body, trabecular meshwork, retina and optic nerve (Fig. 3C) . In mouse, expressions were detected in 7-, 11-, 15-and 17-day-old developing embryos (Fig. 4C) .
Although the in vivo function of WDR36 is yet unknown, identification of this gene as an adult-onset POAG gene provides an opportunity to find and to study biochemical pathways that are expected to be involved in the pathogenesis of this group of optic neuropathies. WDR36 contains multiple G-beta WD40 repeats that are also present in a large family of proteins with diverse functions. As this WD40 repeat motif is also involved in protein -protein interaction and as WDR36 is now implicated in the etiology of POAG, this finding provides an opportunity to search for WDR36-interacting proteins aiming to identify other proteins/genes that have direct functional effect on the pathophysiology of this blinding condition. Additionally, although different mutations in WDR36 were observed in both high-and low-pressure glaucoma, molecular screening of this gene may provide a useful tool for presymptomatic detection of individuals at risk in families or in the elderly population.
MATERIALS AND METHODS
Family ascertainment
The clinical status of all affected POAG members of studied families have previously been confirmed by their respective caring ophthalmologists. The diagnoses of glaucoma agreed with the standard criteria and included abnormal cup/disc ratio and glaucomatous visual field loss with or without increased IOP. The original GLC1G-linked family of POAG-527 has a total of 108 members in five generations, of whom 54 (seven affected, five glaucoma suspect and 42 unaffected) participated in this study. The other large family of POAG-002 that was originally used in our genome scan but subsequently proven to be unlinked to the GLC1G locus has a total of 99 members in four generations, 40 of whom have been sampled previously (13 affected, four OH and 23 unaffected). The clinical status of all other unrelated familial and sporadic POAG subjects screened during this study have previously been confirmed. The University of Connecticut Health Center Institutional Review Board has approved this study for inclusion of Human Subjects in Research.
Genome-wide scan
A genome-wide scan was carried out with two different sets of fluorescently end-labeled primers (ABI and CHLC-Weber linkage mapping sets). The amplified PCR products were loaded onto a 96-well gel and run on an ABI-377 automated DNA sequencer. Computer assisted data collection and genotyping were performed with the ABI GENESCAN analysis and ABI GENOTYPER computer software. The obtained genotypic data were analyzed and further used for additional linkage analysis and saturation mapping.
Saturation mapping and refinement of the GLC1G critical region All genotypes either from the ABI or from the CHLC-Weber florescent linkage mapping sets were automatically transferred into an in-house database management system (DMS) program. Pedigrees and their genotypic data for each of the 22 chromosomes were subsequently exported to the CYRIL-LIC program and haplotypes were constructed for each pedigree and for each chromosome. Co-inheritance of affected-bearing haplotypes with the POAG phenotype was inspected manually for each of the studied families. Using additional short tandem repeat polymorphism (STRP) markers potential regions of interest were saturated in these families. After a hint of linkage was observed on chromosome 5q, fluorescent genotyping and saturation mapping of other families with new STRP markers were carried out in order to reduce the identified interval even further. The two-point and multi-point LOD scores were calculated with the MLINK and LINKMAP components of the LINKAGE program, respectively (30) .
Mutation screening
After linkage to the GLC1G locus was established and its candidate region was reduced to a region of 2 Mb, all the seven known genes mapping to the critical region ( Fig. 1) were selected for mutation screening. Primers were designed to flank intron -exon boundaries of the selected genes and PCR amplification performed using genomic DNA of affected individuals (primer sequences are available on request). Direct sequencing carried out with ABI-Big Dye Terminator Cycle sequencing kit and run on an ABI-3100 Genetic Analyzer and DNA Sequencer.
RNA analysis
Under a dissecting microscope, the lens, iris, ciliary body, ciliary muscle, trabecular meshwork, sclera, retina and optic nerve were micro-dissected and immediately used for RNA extraction. The TRIzol reagent method (Invitrogen) was used to isolate RNA from these ocular tissues. For RT -PCR, cDNA were made from purified RNAs, using random hexamer primers and Superscript III reverse transcriptase (Invitrogen). Furthermore, expression of the WDR36 gene in human and mouse tissues were investigated by northern hybridization. Radiolabeled probes were prepared from a 691 and 693 bp PCR fragment amplified from human and mouse cDNA, respectively. Expression of this gene was studied by use of the same probe and a premade blot (Clontech) containing poly(A)þ mRNA (2 mg/lane) from heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas in human and heart, brain, spleen, lung, liver, skeletal muscle, kidney and testis in mouse.
